Posts by: Marisa Wexler

News

Iomab-B shows promise as a conditioning regimen for bone marrow transplant in patients older than 55 with active relapsed or refractory acute myeloid leukemia (AML), according to early data from ... Read more

January 7, 2021January 7, 2021

Ascentage Pharma’s APG-2575 Earns Orphan Drug Designation

News

APG-2575, an investigational Bcl-2 inhibitor being developed by Ascentage Pharma, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia ... Read more

November 2, 2020November 5, 2020

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

News, syndicated

The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations ... Read more

October 19, 2020October 19, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

News, syndicated

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series ... Read more

September 28, 2020September 28, 2020

First Clinical Trial Launched for AML, Other Blood Cancer Patients With COVID-19

News

The Leukemia & Lymphoma Society (LLS) has announced the launch of the first clinical trial dedicated to people with blood cancers, including acute myeloid leukemia (AML), who are infected with COVID-19. The study ... Read more

September 14, 2020September 14, 2020

French Authorities Advance Phase 3 Trial Testing Sellas’ GPS Cancer Vaccine

News

French regulatory authorities have approved an investigational medicinal product dossier (IMPD) from Sellas Life Sciences, granting permission to advance in France a Phase 3 clinical trial testing the cancer vaccine ... Read more

August 27, 2020August 27, 2020

Venclexta Plus Vidaza Increases AML Survival, Study Shows

News

Adding Venclexta (venetoclax) to treatment with Vidaza (azacitidine) significantly prolongs survival in people with acute myeloid leukemia (AML) who have not been treated before, a new study demonstrates. The study, ... Read more

June 25, 2020June 25, 2020

Cost of Cancer Treatment in US Could Rise by 34% by 2030

News

The cost of treating acute myeloid leukemia (AML) and other cancers in the United States is projected to increase substantially by 2030, a study reports. The study, “Medical Care Costs ... Read more

June 8, 2020June 8, 2020

Intellia Looking to Bring Its Potential T-cell Therapy for AML into Trials

News

Data from early studies suggest that Intellia Therapeutics‘s proprietary CRISPR/Cas9 technology can more effectively generate tumor targeting T-cells than conventional methods, and support testing NTLA-5001, the company’s engineered cell therapy candidate ... Read more

May 28, 2020May 28, 2020

Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports

News

First-line treatment with a combination of Venclexta (venetoclax) and Vidaza (azacitidine) significantly extended survival in people with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, as compared with Vidaza alone, AbbVie ... Read more